Pharmacy World and Science

, Volume 19, Issue 4, pp 191–196 | Cite as

Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.

  • J. Zoer
  • A.M. Schrander-van der Meer
  • W.T. van Dorp


The standard dosage of vancomycin in haemodialysis patients is usually 1 gram, once a week. The aim of our study was to investigate vancomycin clearance by two highly permeable membranes and to determine whether dosage adjustment is necessary in regular haemodialysis settings when using these type of dialyzers.

12 patients on regular haemodialysis and treated with vancomycin either prophylactically or therapeutically were prospectively randomised to either dialysis with a polyacrylonitril parallel membrane (AN‐69®) or a cellulose‐acetate hollow fiber membrane. After administering vancomycin to the patient vancomycin plasma levels were measured at different intervals. The vancomycin clearance by the dialyzer was calculated from blood samples taken 1 hour after commencing dialysis. The data were used for pharmacokinetic computer simulation in order to develop a vancomycin dosage regimen for patients on regular haemodialysis with highly permeable membranes. The mean vancomycin dialysis clearance was 46 ± 5 ml/min and did not differ between the two artificial kidneys. Dialysis clearance of vancomycin was independent of blood flow rate.

Together with the dialyzer data a pharmacokinetic profile of each patient was calculated from the plasma samples. The average non‐renal clearance was 3.3 ml/min/1.73 m2 while renal vancomycin clearance, as a fraction of creatinine clearance, was found to be 0.83 ± 0.20. The computer calculations predicted that, irrespective of residual renal function, in most patients on regular haemodialysis and treated with these type of artificial kidneys, therapeutic and non‐toxic vancomycin levels could be obtained by giving 1000 mg of vancomycin intravenously as a loading dosage and 500 mg during every subsequent dialysis.

Haemodialysis Vancomycin Renal insufficiency Dosage 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594–8.Google Scholar
  2. 2.
    Matzke GR, Zhanel GG, Guay DRP. Clinical Pharmacokinetics of vancomycin. Clin Pharmacokin 1986;11:257–82.Google Scholar
  3. 3.
    Bastani B, Spyker DA, Minocha A, Cummings R, Westervelt FB. In vivo comparison of three different hemodialysis mem-branes for vancomycin clearance: Cuprophan, cellulose acetate and polyacrylonitrile. Dial Transplant 1988;17:527–43.Google Scholar
  4. 4.
    Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J, et al. Pharmacokinetics of vancomycin in patients undergo-ing hemodialysis with polyacrylonitrile. Clin Nephrol 1991;36:35–41.Google Scholar
  5. 5.
    Lanese DM, Alfrey PS Molitoris BA. Markedly increased clear-ance of vancomycin during haemodialysis using polysulfon dialyzers. Kidney Int 1989;35:1409–12.Google Scholar
  6. 6.
    Cunha BA, Quintiliani R, Deglin JM, Irard MW, Nightingale CH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 1981;3:S269–S72.Google Scholar
  7. 7.
    Tan CC, Lee HS, Ti Ty, Lee EJC. Pharmacokinetics of intrave-nous vancomycin in patients with end-stage renal failure. Ther Drug Monit 1990;12:29–34.Google Scholar
  8. 8.
    De Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 1989;4:635–9.Google Scholar
  9. 9.
    White LO, Edwards R, Holt HA, Lovering AM, Finch RG, Reeves DS. The in vitro degradation at 37°C in serum, CAPD fluid and phosphate buffered saline. J Antimicrob Chemother 1988;22:739–45.Google Scholar
  10. 10.
    Lee CC, Marbury TC. Drug therapy in patiënts undergoing haemodialysis. Clin Pharmacokin 1984;9:42–66.Google Scholar
  11. 11.
    Van Stone JC. Haemodialysis apparatus. In: Daugirdas JT and Ing TS, eds. Handbook of dialysis. Boston: Little Brown and Company 1988; chapter 3:21–39.Google Scholar
  12. 12.
    Hoenick NA, Kerr DNS. Dialysers. In: Drukker W, Parsons FM and Maher JF, eds. Replacement of renal function by dialysis. Boston: Martinus Nijhoff Publishers, 1986:122–3.Google Scholar
  13. 13.
    Hurst AH, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC. Application of a Bayesian method to monitor and adjust vancomycin regimens. Antimicrob Agents Chemother 1990;34:1165–71.Google Scholar
  14. 14.
    Böhler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer PJ. Rebound of plasma vancomycin after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol 1992;42:635–40.Google Scholar
  15. 15.
    Newfield P, Roizen MF. Hazards of Rapid Administration of vancomycin. Ann Intern Med 1979;91:581.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • J. Zoer
    • 1
  • A.M. Schrander-van der Meer
    • 2
  • W.T. van Dorp
    • 2
  1. 1.Central Pharmacy of the Haarlem HospitalsHaarlemThe Netherlands
  2. 2.Department of Internal Medicine and NephrologyKennemer GasthuisHaarlemThe Netherlands

Personalised recommendations